ArticleACS medicinal chemistry letters2017
Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Saga of MCL1 inhibitors in multiple myeloma.Biochemical pharmacology · 2026Review
- Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen.ACS medicinal chemistry letters · 2024Article
- Small molecules targeting protein-protein interactions for cancer therapy.Acta pharmaceutica Sinica. B · 2023Review
- Small-molecule discovery through DNA-encoded libraries.Nature reviews. Drug discovery · 2023Review
- Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Scanning Protein Surfaces with DNA-Encoded Libraries.ChemMedChem · 2021Review
- Recent Progress Using De Novo Design to Study Protein Structure, Design and Binding Interactions.Life (Basel, Switzerland) · 2021Review
- Review
- Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1.ACS omega · 2019Article
- Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry.Molecules (Basel, Switzerland) · 2019Article
- Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery.Molecules (Basel, Switzerland) · 2019Review
- A Mild, DNA-Compatible Nitro Reduction Using BOrganic letters · 2019Article
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.Nature communications · 2018Article
- A structural investigation of NRZ mediated apoptosis regulation in zebrafish.Cell death & disease · 2018Article
- Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.Cell chemical biology · 2017Review
- Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer.Signal transduction and targeted therapyArticle
Corrections and comments
- Erratum issued
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mcl-1 is a pro-apoptotic BH3 protein family member similar to Bcl-2 and Bcl-xL. Overexpression of Mcl-1 is often seen in various tumors and allows cancer cells to evade apoptosis. Here we report the discovery and optimization of a series of non-natural peptide Mcl-1 inhibitors. Screening of DNA-encoded libraries resulted in hit compound
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.